Anaptysbio ANAB
NASDAQ ANAB
$56.80 -0.66 (-1.15%)
As of: Sep 4, 2026 · 2:32 PM EDT

Anaptysbio (ANAB) Operating Income (QoQ) (2016 - 2026)

Analysis

Anaptysbio (ANAB) Operating Income (QoQ) (2016 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn
8 Royalty Pharma 28.40 Bn 27.56 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 Anaptysbio 1.63 Bn 1.34 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -151.77%
Dec 31, 2025 92.78%
Sep 30, 2025 232.61%
Jun 30, 2025 4.97%
Mar 31, 2025 -184.79%
Dec 31, 2024 57.51%
Sep 30, 2024 43.56%
Jun 30, 2024 4.45%
Mar 31, 2024 -0.16%
Dec 31, 2023 -11.67%
Sep 30, 2023 6.01%
Jun 30, 2023 9.59%
Mar 31, 2023 -70.95%
Dec 31, 2022 12.35%
Sep 30, 2022 -6.60%
Jun 30, 2022 12.44%
Mar 31, 2022 -1.90%
Dec 31, 2021 -360.70%
Sep 30, 2021 -1,168.86%
Jun 30, 2021 97.10%